PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers

Overview of attention for article published in Gynecologic Oncology Research and Practice, November 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 1 news outlet

Citations

dimensions_citation: 43 Dimensions

Readers on

mendeley: 73 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 1 news story.

What to know about HRD testing for ovarian cancer

Medical News Today, 30 May 2022

Homologous recombination deficiency (HRD) is a biomarker present in most advanced stages of ovarian cancer.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.